For example, the inclusion criteria of the clinical trials NCT05420519, targeting CD70, and NCT04969354, targeting CAIX, both had patients with advanced RCC who have failed first-line and second-line therapies (including ICIs). Here, CA9 is linked to renal cell carcinoma.